AXL and neoplasm: As the TAM RTKs are known to negatively regulate inflammatory immune responses [5, 9], high DN10764 dosing may have targeted both AXL and MERTK, resulting in hyperinflammation in vivo, ultimately contributing to the promotion of tumor progression and metastasis.